Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WSC 2026 | Infarct growth rate in acute ischemic stroke: measuring fast vs slow progressors

Giorgio Busto, MD, Careggi University Hospital, Florence, Italy, discusses infarct growth rate in acute ischemic stroke and how it can be used to risk-stratify patients for treatment. Dr Busto explains that infarct growth rate is heterogeneous between patients, allowing them to be classified as fast or slow progressors. He outlines imaging-based methods to assess infarct growth in clinical practice, explaining that fast progressors may benefit from rapid transfer for thrombectomy and neuroprotective drugs, while slow progressors may benefit most from endovascular thrombectomy. This interview took place at the 18th World Stroke Congress (WSC) in Seoul, Korea.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Infarct growth rate is the progressive transformation of the ischemic penumbra, the tissue that could be saved if swiftly reperfused, into infarct tissue that is no longer viable. Basically, each patient will do that until reperfusion is achieved, but the speed of this progression is highly heterogeneous among patients. And it depends on several factors like cell types, oxygen delivery, glucose levels, but primarily on cerebral blood flow fluctuations...

Infarct growth rate is the progressive transformation of the ischemic penumbra, the tissue that could be saved if swiftly reperfused, into infarct tissue that is no longer viable. Basically, each patient will do that until reperfusion is achieved, but the speed of this progression is highly heterogeneous among patients. And it depends on several factors like cell types, oxygen delivery, glucose levels, but primarily on cerebral blood flow fluctuations. Depending on the infarct growth rate, patients can be categorized into specific progressor phenotypes, namely fast or slow progressor, with crucial clinical implications. Basically, you have three different modalities to assess the infarct growth rate. The first one is to realize a ratio between ischemic core volume, estimated by CT perfusion or non-contrast CT or MRI, and the time elapsed from symptom onset to imaging. The second one is the ratio between the infarct-core volume, assessed by diffusion-weighted imaging, and the time elapsed from symptom onset to imaging. And the last one are perfusion-based methods, which rely on the identification of arterial and tissue collaterals, regardless of knowing the time from symptom onset. This is important to assess the infarct growth because patients can be managed differently when you want to identify those fast progressors that could benefit from fast reperfusion and have to be transferred rapidly from a bespoke to a thrombectomy-capable stroke center. Then, identifying those fast progressors that could benefit from neuroprotective drugs that freeze or slow down infarct growth is another important thing to do. And at last, another important thing is to improve risk stratification, identifying those slow progressors that could benefit the most from endovascular thrombectomy because they are capable of reaching better outcomes differently from those fast progressors.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.